H1N1 Vaccine Market, By Vaccine Type (Inactivated Vaccine, and Live Attenuated Vaccine), By Route of Administration (Injectable Vaccine, and Intranasal Vaccine), By Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies), and Region - Trends, Analysis and Forecast till 2034

Report Code: PMI11919 | Publish Date: March 2024 | No. of Pages: 178

Global HN Vaccine Market By Overview

H1N1 Vaccine Market was valued at US$ 4  Billion in 2024 and is projected to grow at a CAGR of 7.4%to reach US$ 7.6 Billion by 2034.

H1N1 flu also known as swine flu is an infectious disease which is spread by pigs or swine’s. Swine flu mainly affects the respiratory system. The H1N1 vaccines are mostly used to build immunity against swine flu to reduce further chances of infections. The global H1N1 vaccine is expected to show a significant growth over the forecast period owing to development and launches of novel H1N1 vaccines in the market. For instance, in September 2018, Institute of Vaccines and Medical Biologicals (IVAC) has developed two vaccine namely IVACFLU-S and IVACFLY. IVACFLU-S provides immunity against the Influenza B virus and the H1N1, H3N2 subtypes of the Influenza A virus, while IVACFLY provides immunity against the H5N1 subtype of the Influenza A virus. Both vaccines have passed clinical trials is expected to launch soon in Vietnam market. In 2015, Serum Institute of India launched 65,000 doses of NasoVac S, a swine flu (H1N1) vaccine, which is administered as a nasal drop, follows a spurt in cases of H1N1. Furthermore, breakout of H1N1 Flu Virus (Swine Flu) in key regions is expected to drastically rise the demand for its vaccines over the forecast period to prevent further exposure to such life threatening disease. For instance, as per the Centers of Disease Control and Prevention estimates in 2009 there were around1.8 million to 5.7 million symptomatic cases of pandemic (H1N1) in the U.S., which resulted around 9,000–21,000 hospitalizations. In 2015, H1N1 Flu Virus (Swine Flu) broke out in some regions of India and caused around 33,000 laboratory confirmed cases and around 2,000 death in India. Hence, such breakouts of H1N1 in key region are expected to significantly rise demand for its vaccines

Global HN Vaccine Market By Segmentation

H1N1 vaccine market has been segmented on the basis of vaccine type, route of administration, distribution channel, and region.

  • On the basis of vaccine type, the global H1N1 Vaccine Market has been segmented in inactivated vaccine, and live attenuated vaccine.
  • On the basis of route of administration, the global H1N1 vaccine market has been segmented in injectable vaccine, and intranasal vaccine.
  • On the basis of distribution channel, the global H1N1 vaccine market has been segmented in hospital, retail pharmacies, and online pharmacies.
  • On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and & Africa. North America is expected to account major market share as compared to that of other regions.

HN Vaccine Market Report Scope:

Attribute

Details

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Vaccine Type: Inactivated Vaccine, and Live Attenuated Vaccine

By Route of Administration: Injectable Vaccine, and Intranasal Vaccine

By Distribution Channel: Hospital, Retail Pharmacies, and Online Pharmacies

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the H1N1 Vaccine Market report based on type, treatment, end-users and region:

H1N1 Vaccine Market, By Vaccine Type:

  • Inactivated Vaccine
  • Live Attenuated Vaccine

H1N1 Vaccine Market, By Route of Administration:

  • Injectable Vaccine
  • Intranasal Vaccine

H1N1 Vaccine Market, By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies

H1N1 Vaccine Market, By Region:

  • North America
    • Middle East & Africa
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
      • U.S.
      • Canada

Global HN Vaccine Market By Key Players

The key players operating the H1N1 Vaccine Market includes, GlaxoSmithKlinePlc, AstraZeneca Plc., Medimmune, Serum Institute of India, Novartis AG, Abbott Laboratories, Lupin Ltd., Sanofi S.A., CSL Biotherapeutics, Sinovac, ID Biomedical Corporation, Cadila Healthcare, and Others.

Highlights and Scope of H1N1 Vaccine Market Report:

  • Definition, description, overview of market growth influencing factors, and forecast for the target market
  • Scope for related market in the forecast period
  • Analysis and outcome for the H1N1 Vaccine Market by segment and region followed by countries
  • Market segmentation, dominating segment and region followed by country along with market value, share, Y-o-Y growth, CAGR, forecast, and contribution in the market
  • Key market player profiles, their recent developments, strategies, financial details, key competencies, presence by region, and product portfolio
  • Valuable insights, data, and forecast that can be referenced to plan business strategies, to tap market opportunities, understand business related risks, derive business goals, to recognize trends, and understand target customers/end users
  • Insights on recent technologies, pipeline products, regulations related with target market, market investment, and offers insights on political and economic factors that may influence market growth
  • PEST Analysis, PORTER’s five forces analysis, opportunity map analysis, drivers and restraints impact analysis, and market attractiveness index.

Global HN Vaccine Market By Company Profile

  • GlaxoSmithKlinePlc*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AstraZeneca Plc.
  • Medimmune, Serum Institute of India
  • Novartis AG
  • Abbott Laboratories
  • Lupin Ltd
  • Sanofi S.A.
  • CSL Biotherapeutics
  • Sinovac
  • ID Biomedical Corporation
  • Cadila Healthcare. 

“*” marked represents similar segmentation in other categories in the respective section

Global HN Vaccine Market By Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
    • PORTER’s
    • Investment Outlook
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for H1N1 Vaccine Strategies
      • Key Questions this Study will Answer
      • By Vaccine Type (Inactivated Vaccine, and Live Attenuated Vaccine)

        By Route of Administration (Injectable Vaccine, and Intranasal Vaccine)

        By Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies)

    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Overview
    • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
    • Y-o-Y Growth Analysis (%), 2024 – 2034
    • Regional Trends
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Regional Analysis
    • Regional Revenue Analysis
    • Regional By segment Analysis
    • Reasons for regional growth
    • Key Player of particular region
    • Countries Include in the report:
  1. North America (U.S., Canada)
    • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)
    • Latin America (Brazil, Mexico, Rest of Latin America)
    • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
    • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
  1. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
    • Competitive Overview
    • Competitive Benchmarking
    • Market Share Analysis
    • Key Developments In The Global H1N1 Vaccine Market
    • Key Developments: Mergers & Acquisitions
    • Key Developments: Collaboration
    • Key Developments: Contracts & Agreements
    • Key Developments: Expansion
    • Key Developments: Product Developments
  2. Company Profiles
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
  • SWOT Analysis
    • GlaxoSmithKlinePlc

    • AstraZeneca Plc.

    • Medimmune

    • Serum Institute of India

    • Novartis AG

    • Abbott Laboratories

    • Lupin Ltd.

    • Sanofi S.A

    • CSL Biotherapeutics

    • Sinovac

    • ID Biomedical Corporation

    • Cadila Healthcare, and Others.

  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The H1N1 vaccine market has been segmented on the basis of vaccine type, route of administration, distribution channel, and region.

Key players operating in the H1N1 vaccine market includesGlaxoSmithKlinePlc, AstraZeneca Plc., Medimmune, Serum Institute of India, Novartis AG, Abbott Laboratories, Lupin Ltd., Sanofi S.A., CSL Biotherapeutics, Sinovac, ID Biomedical Corporation, Cadila Healthcare, and Others.

High cost of drug might hamper the market.

The H1N1 vaccine is expected to show a significant growth over the forecast period owing to development and launches of novel H1N1 vaccines in the market.

North America is expected to account major market share as compared to that of other regions.